Tuesday, April 27, 2021 2:47:51 PM
ABUS
1) May 4th Appeals Briefs due in MRNA vs ABUS 069. Oral next. ABUS asked for extension.ABUS
1) May 4th Appeals Briefs due in MRNA vs ABUS 069. Oral next. ABUS asked for extension.
2) May 5th. HBV Virtual Summit
3) May 10ish 2021, Expected Q1 Earnings Report. Has NOT been announced but was May 11, 2020
4) NO major PR since mid March, PR challenged. Last HBV trial news was Dec. 10th, 90 days was due March 10th
5) Annual Meeting email sent April 22nd. Meeting May 23rd
6) Requested 9M shares in Comp. Plan in 2021 vs 3M in 2020.
7) Announced
$75M
Offering last meeting. ATM. At $3.75/share, that's 20,000,000 shares. Averaged 2M a month from Oct 2020 to March 2021.
OS rose from 85M to 96M
8) October 2021, MANDATORY conversion of preferred shares owned by Roivant for repayment of loan 5 years ago.
24 million shares at $7. Roivant/Vivek will then own 40M ABUS shares.
9) Oct, 2021 - 5 year "No Buy" expires. Roivant can buy ABUS shares
10) Sophie developed cure for HepC!
11) Pipeline!!! AB 729 PT COVID P1 ends 4/30
12) Gritstone
13) Genevant
AND;
$ABUS WOW FOR DIS INFRINGEMENT OF PATENTS MRNA CONTINUES TO GROW !!!!!
MRNA
MarketWatch • 2 hours ago
U.S. buys another 100 million COVID-19 vaccine candidate doses:
Moderna
IS VERY SUCCEESSFUL SO FAR IN THEIR VACCINE
Recent ABUS News
- Arbutus to Participate in Two Upcoming Investor Conferences • GlobeNewswire Inc. • 09/03/2024 11:30:00 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/08/2024 08:17:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/05/2024 08:13:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 11:31:17 AM
- Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 08/01/2024 11:30:00 AM
- Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update • GlobeNewswire Inc. • 07/18/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 03:16:15 PM
- Treatment with Arbutus’ Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels • GlobeNewswire Inc. • 06/06/2024 03:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 10:00:21 AM
- Arbutus’ Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure • GlobeNewswire Inc. • 06/05/2024 06:30:00 AM
- Arbutus to Participate in Jefferies Global Healthcare Conference • GlobeNewswire Inc. • 05/29/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/28/2024 08:25:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/24/2024 08:10:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/24/2024 08:07:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2024 10:00:18 AM
- Arbutus to Present Imdusiran Data at EASL Congress 2024 • GlobeNewswire Inc. • 05/22/2024 06:00:00 AM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 05/17/2024 01:03:23 PM
- Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value • Business Wire • 05/17/2024 01:00:00 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 05/09/2024 12:00:20 PM
- Arbutus to Participate in Two Upcoming Investor Conferences • GlobeNewswire Inc. • 05/07/2024 11:30:00 AM
- Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024 • GlobeNewswire Inc. • 05/02/2024 11:25:00 AM
- Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update • GlobeNewswire Inc. • 04/18/2024 11:30:00 AM
- Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna • GlobeNewswire Inc. • 04/04/2024 12:30:49 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM